Neurocrine Biosciences announced late last month at an industry conference in Spain encouraging results from its latest findings regarding management of tardive dyskinesia (TD).
The latest report from the neuroscience-focused biopharmaceutical company buoyed Neurocrine’s stock price (NBIX:NASDAQ) by more than 5%.
Wall Street investors have applauded the company’s recent progress, allowing the San Diego-based firm’s shares to trade near 52-week highs of $109. NBIX is currently showing a more than 20% gain in 2022 while returns on the SP 500 at the start of Q4 are down more than 20% YTD.
At the MDS International Congress of Parkinson’s Disease and Movement Disorders, held September 15-18 in Madrid, Neurocrine said its latest survey findings demonstrate the need for education on supportive evidence regarding best approaches to managing TD symptoms while maintaining control of the underlying psychiatric disorder
Neurocrine’s case-based survey assessed practice, knowledge and attitudes of psychiatrists and neurologists, including a subset of movement disorder specialists in the U.S., in managing of patients with TD.
Survey results show the prevalence of TD cases continue to be underestimated. “Over time, more respondents are considering pharmacologic therapy as initial management for patients with TD and opting for a VMAT2 inhibitor to manage TD movements,” the company said.
The most common patient complaints prompting treatment for TD were “patient embarrassment/social anxiety” and “effect on quality of life.”
The most significant perceived barrier to optimal management of TD continues to be “apprehension of losing control of the patient’s underlying psychiatric symptoms,” the survey reported.
Importance of Education
“These survey findings demonstrate the continued importance of education for clinicians in the proactive screening, recognition, and treatment of TD as standard of care for at-risk populations,” said Eiry W. Roberts, MD, chief medical officer at Neurocrine Biosciences.
“Management of TD in conjunction with maintaining control of the underlying psychiatric disorder is of key importance,” Roberts added. “Neurocrine Biosciences is committed to furthering education on supportive evidence regarding pharmacologic approaches to the treatment of TD.”
Tardive dyskinesia is a movement disorder characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds of mental health medicines (like antipsychotics) that help control dopamine receptors in the brain.
Taking antipsychotics commonly prescribed to treat mental illnesses such as depression, bipolar disorder, schizophrenia and schizoaffective disorder, and certain medications to treat upset stomach, nausea and vomiting are associated with TD.
In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement.
TD is estimated to affect approximately 600,000 people in the U.S. The symptoms can be severe and are often persistent and irreversible.
Neurocrine Biosciences focuses on discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids, as well as over a dozen mid- to late-stage clinical programs in multiple therapeutic areas.
In August, Neurocrine established a research and commercial foothold in Europe with its acquisition of U.K. specialty pharma firm Diurnal Group. The all-cash deal was reportedly valued at 48.3 million British pounds – or roughly $56.5 million.
CEO: Kevin C. Gorman, Ph.D.
HEADQUARTERS: San Diego
REVENUE: $1.13 billion (2021)
STOCK: NBIX (NASDAQ)
NOTABLE: The company’s motto is: ‘You Deserve Brave Science’